NCT00041600 Human Epilepsy Genetics--Neuronal Migration Disorders Study
| NCT ID | NCT00041600 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Harvard University Faculty of Medicine |
| Condition | Brain Malformation |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,500 participants |
| Start Date | 1996-04 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,500 participants in total. It began in 1996-04 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to identify genes responsible for epilepsy, brain malformations and disorders of human cognition.
Eligibility Criteria
INCLUSION: * Males and females of any age. * Persons with a brain malformation or disorder of cognition (familial intellectual disability \[previously known as mental retardation\] or autism). EXCLUSION: * Persons without a brain malformation or disorder of cognition (familial intellectual disability (previously known as mental retardation\] or autism).
Contact & Investigator
Christopher A. Walsh, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
Harvard Institutes of Medicine
Frequently Asked Questions
Who can join the NCT00041600 clinical trial?
This trial is open to participants of all sexes, studying Brain Malformation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00041600 currently recruiting?
Yes, NCT00041600 is actively recruiting participants. Contact the research team at walshresearch@childrens.harvard.edu for enrollment information.
Where is the NCT00041600 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT00041600 clinical trial?
NCT00041600 is sponsored by Harvard University Faculty of Medicine. The principal investigator is Christopher A. Walsh, M.D., Ph.D. at Harvard Institutes of Medicine. The trial plans to enroll 3,500 participants.